Bal Pharma clarified on August 25, 2026, that the tentative timeline for utilizing net proceeds from its preferential issue of convertible warrants is 18 months from the date of allotment. This disclosure aligns with the tenure of the warrants as per SEBI regulations.

The company issued the clarification under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It cited Regulation 162 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, which governs the utilization period for such instruments. The timeline is subject to receiving in-principle approval from the stock exchanges.

Regulatory Context

Bal Pharma stated that there is no change in the objects of the preferential issue or the manner of proceeds utilization. The intimation serves solely to clarify the tentative timeline based on the 18-month tenure of the convertible warrants. The company directed investors to treat this information as a formal record.

Shreepada ML, Company Secretary and Compliance Officer, signed the disclosure. The notice was sent to both the National Stock Exchange of India Limited and BSE Limited.

Bal Pharma Limited has released its unaudited standalone financial results for the first quarter of FY27, ending June 30, 2026. The Board of Directors approved the results in a meeting held on August 12, 2026. While specific financial metrics were not detailed in the immediate press release, the full format of the results is available on the company’s website and stock exchange portals.

In a separate compliance move, the company issued a notice regarding the transfer of unclaimed equity shares to the Investor Education and Protection Fund (IEPF) Authority. Under Sections 124 and 125 of the Companies Act, 2013, shares belonging to shareholders who have not claimed dividends for seven consecutive years are liable for transfer.

Key Compliance Details

The notice applies to dividends declared from FY2018-19 onwards. Shareholders affected by this provision must take action to retain their holdings:

• Deadline: Claims must be submitted on or before October 30, 2026.
• Action Required: Shareholders must apply to the Registrar and Transfer Agents (RTA), M/s. TSR Consultants Private Limited.
• Consequence: Failure to claim shares and dividends by the deadline will result in the transfer of these assets to the demat account of the IEPF Authority.

The company emphasized that no claims will lie against Bal Pharma or its RTA for amounts or shares transferred to the IEPF after the deadline. However, shareholders can still recover their assets by following the procedure stipulated in the IEPF Rules.

What the Numbers Show

The release of Q1FY27 results coincides with significant regulatory compliance actions regarding dormant shareholder accounts. This dual announcement highlights the company's focus on both operational transparency through quarterly reporting and statutory adherence to investor protection norms. The strict October deadline underscores the urgency for long-term investors to verify their dividend claim status.